GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » EV-to-Revenue

NKGen Biotech (NKGen Biotech) EV-to-Revenue : (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NKGen Biotech's enterprise value is $57.52 Mil. NKGen Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil. Therefore, NKGen Biotech's EV-to-Revenue for today is .

The historical rank and industry rank for NKGen Biotech's EV-to-Revenue or its related term are showing as below:

NKGN's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.18
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-26), NKGen Biotech's stock price is $1.42. NKGen Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00. Therefore, NKGen Biotech's PS Ratio for today is .

NKGen Biotech EV-to-Revenue Historical Data

The historical data trend for NKGen Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech EV-to-Revenue Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
EV-to-Revenue
- - -

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of NKGen Biotech's EV-to-Revenue

For the Biotechnology subindustry, NKGen Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's EV-to-Revenue falls into.


NKGen Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

NKGen Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=57.521/0
=

NKGen Biotech's current Enterprise Value is $57.52 Mil.
NKGen Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech  (NAS:NKGN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

NKGen Biotech's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.42/0
=

NKGen Biotech's share price for today is $1.42.
NKGen Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » EV-to-Revenue
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.